Granada

• ​​AMG 436 as monotherapy and combination therapy in participants with Microsatellite Instability-High/Mismatch Repair Deficient Solid Tumors … Pending
  2025-524056-63-00 1 microsatellite instability high/mismatch repair deficient (MSI-H/dMMR)
• A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Pending
  2025-524078-40-00 5 Chronic Spontaneous Urticaria
• Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients … Pending
  2025-524103-69-00 10 Chronic Venous Insufficiency
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Pending
  2025-524408-30-01 5 Metastatic hormone-sensitive prostate cancer
• Optimizing Aspirin Use for Preeclampsia Prevention Pending
  2025-524646-94-00 11 Obstetrics – Preeclampsia
• SIE-1 Recruiting
  2025-523269-31-00 3 2026-06-02 Hormone receptor-positive early breast cancer in post-menopausal women
• Study to Assess K1-70 in Participants with Active Thyroid Eye Disease Recruiting
  2024-519292-26-00 4 2026-05-28 Graves’ disease and active thyroid eye disease
• A Phase 3 Study Comparing JNJ-79635322 and an anti-BCMAxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma Recruiting
  2025-522007-18-00 5 2026-05-27 Relapsed or Refractory Multiple Myeloma
• MAVRiC studies 2L treatment with AV in patients with CLL/SLL who have relapsed after a course of BTKi + BCL2i combination, with and without … Recruiting
  2024-518858-17-00 4 2026-05-22 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B … Recruiting
  2025-522255-25-00 5 2026-05-18 Fallopian Tube Neoplasms
• A Clinical Trial to Compare the Effectiveness and Safety of RO7771950 in Combination with Trastuzumab and Capecitabine, Versus Tucatinib in … Recruiting
  2025-524498-17-00 10 2026-05-08 Pretreated Unresectable Locally Advanced or Metastatic human epidermal
• Phase 3 study comparing ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and … Recruiting
  2025-522996-27-00 5 2026-05-05 recurrent and/or metastatic squamous cell carcinoma of the head and ne
• Phase 2 Proof-of-Concept Study of LAD328 in Adults with Hidradenitis Suppurativa Recruiting
  2025-521865-29-00 4 2026-04-30 moderate-to-severe hidradenitis suppurativa
• A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB 3111) Compared With Venetoclax Plus Acalabrutinib in Patients With Pre … Recruiting
  2025-524366-21-00 5 2026-04-29 treatment-naive Chronic Lymphocytic Leukemia
• A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve … Recruiting
  2025-523013-28-00 4 2026-04-07 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting
  2025-522279-27-00 5 2026-04-02 Newly Diagnosed AML with an NPM1 mutation
• VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA) Recruiting
  2024-512436-29-00 11 2026-03-27 CARDIOVASCULAR DISEASES
• A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants wit … Recruiting
  2025-523204-68-00 4 2026-03-25 HER2-positive breast cancer
• PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C … Recruiting
  2024-520027-88-00 4 2026-02-12 Patients with hormone receptor-positive (HR+) breast cancer
• A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me … Recruiting
  2025-521919-39-00 3 2026-02-10 Resected stage IIB, IIC, or III melanoma requiring adjuvant treatment
• A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis Recruiting
  2024-520337-80-00 5 2026-01-07 Palmoplantar Pustulosis
• A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear … Recruiting
  2023-505661-89-00 4 2025-12-19 Early-stage, Hormone Receptor (HR)-positive / Human Epidermal Growth F

Showing 25–48 of 382 trials